HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ortho Pharmaceutical v. Cosprophar

This article was originally published in The Rose Sheet

Executive Summary

U.S. Court of Appeals for the Second Circuit upholds a lower court's dismissal of Ortho's complaint that Cosprophar's ads for its Anti-Age cosmetics line were misleading and damaging to Ortho's sales of the prescription drug Retin-A (transretinoic acid) ("The Rose Sheet" Aug. 16, 1993, p. 4). The appeals court rules that Ortho has not shown that its interests were damaged because the firm failed "to submit proof demonstrating that consumers view Cosprophar's products as a comparable substitute for Ortho's drugs." In addition, it affirms the lower court's finding that Ortho did not provide evidence showing that consumers were misled by Cosprophar's advertising. Cosprophar's Anti-Age line contains retinol, a cosmetic ingredient, which Cosprophar's ads said "belongs to the same family" as transretinoic acid and is similarly "effective in reducing wrinkles"
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS000776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel